

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



麗珠醫藥集團股份有限公司

LIVZON PHARMACEUTICAL GROUP INC.*

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 1513)

SUPPLEMENTAL ANNOUNCEMENT ON THE PROPOSED PROFIT DISTRIBUTION PLAN FOR THE YEAR ENDED 31 DECEMBER 2025

Reference is made to the English version of Annual Report for the Year ended 31 December 2025 and the audited results announcement for the Year ended 31 December 2025 of Livzon Pharmaceutical Group Inc.*(麗珠醫藥集團股份有限公司) (the “**Company**”) dated 24 March 2026 (collectively, the “**Announcements**”) in relation to, among others, the proposed profit distribution plan for the Year 2025. Unless the context otherwise requires, terms used in this announcement shall have the same meanings as those defined in the Announcements.

To ensure that all Shareholders have a clear and accurate understanding of the arrangements of the proposed profit distribution plan for the Year 2025, the Company hereby sets out the explanation on its content as follows:

The Company's proposed profit distribution plan for the Year 2025 is: based on the total share capital on the equity registration date determined by the implementation of the 2025 profit distribution plan, a cash dividend of RMB14.30 (tax inclusive) will be distributed to all shareholders for every 10 shares held, rather than a cash dividend of RMB14.30 per share (tax inclusive) will be distributed to all shareholders. There will be no bonus shares, nor will the capital reserves be capitalized. This proposed profit distribution is subject to the review and approval of the Company's 2025 Shareholders' meeting.

Save for the supplemental and clarified content set out above in this announcement, all other information and contents contained in the Announcements remain unchanged. This announcement is a supplemental document to the Announcements and should be read in conjunction with the Announcements.

By order of the Board
Livzon Pharmaceutical Group Inc.*
麗珠醫藥集團股份有限公司
Liu Ning
Company Secretary

Zhuhai, China
26 March 2026

As at the date of this announcement, the Executive Director of the Company is Mr. Tang Yanggang (Vice Chairman); the Non-Executive Directors of the Company are Mr. Zhu Baoguo (Chairman), Mr. Lin Nanqi and Mr. Qiu Qingfeng; the Employee Representative Director of the Company is Ms. Ran Yongmei; and the Independent Non-Executive Directors of the Company are Mr. Bai Hua, Mr. Luo Huiyuan, Ms. Cui Lijie and Ms. Wang Zhiyao.

** For identification purpose only*